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Coronary artery disease (CAD) is a leading global cause of morbidity and mortality, and improvements in the diagnosis and treatment of CAD
can reduce the health and economic burden of this condition. Fractional flow reserve (FFR) is an evidence-based diagnostic test of the physio-
logical significance of a coronary artery stenosis. Fractional flow reserve is a pressure-derived index of the maximal achievable myocardial blood
flow in the presence of an epicardial coronary stenosis as a ratio to maximum achievable flow if that artery were normal. When compared with
standard angiography-guided management, FFR disclosure is impactful on the decision for revascularization and clinical outcomes. In this article,
we review recent developments with FFR in patients with stable CAD and recent myocardial infarction. Specifically, we review novel devel-
opments in our understanding of CAD pathophysiology, diagnostic applications, prognostic studies, clinical trials, and clinical guidelines.
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Introduction
Fractional flow reserve (FFR) is a whole cardiac cycle pressure-derived
index of the maximum achievable blood flow in a coronary artery with a
stenosis expressed as a ratio of maximum achievable blood flow if that
artery were normal.1 Fractional flow reserve is a means of assessing the
physiological significance of a coronary artery stenosis. Some of the
most important clinical trials involving patients with coronary artery dis-
ease (CAD) have assessed and confirmed the validity of FFR as a pre-
dictor of outcome. Fractional flow reserve citations in biomedical
journals are increasing2 and FFR-guided management in patients with
stable CAD now has Class I and Class IIa guideline recommendations.3,4
We consider recent studies clarifying further the role of FFR in
patients with stable CAD and myocardial infarction (MI). We focus
on research published from 2013 to the present, whilst also citing
relevant landmark publications. We have searched databases, i.e.
PUBMED and registries, i.e. http://www.clinicaltrials.gov, using the
following key words: ‘fractional flow reserve’, ‘coronary physiology’,
‘diagnostic’, ‘stable coronary disease’, ‘acute coronary syndrome’,
‘myocardial infarction’, ‘observational study’, and ‘clinical trial’. The
results include an assessment of study quality criteria5,6 (Supple-
mentary material online, File S1).
Fractional flow reserve: new
insights into clinical significance
Coronary artery disease is a leading global cause of morbidity and
mortality.7– 9 Invasive angiography is the reference test for the diag-
nosis of CAD. However, the relationship between angiographic
stenosis severity and coronary blood flow is complex. Visual assess-
ment of stenosis severity is subjective and correlates poorly with
physiological significance. More objective measurements of stenosis
severity using quantitative coronary analysis (QCA) are also com-
monly discordant with the physiological significance of the lesion,
as defined by FFR (≤0.80).10
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Coronary physiology and stenosis
flow dynamics
In the presence of an obstructive epicardial coronary stenosis, per-
fusion pressure is reduced leading to compensatory vasodilata-
tion,1,11,12 which itself has prognostic importance.13 The total
pressure drop across a stenosis is defined by the sum of the viscous
friction along the entrance of a lesion (increasing with flow in a linear
manner, Poiseuille’s Law), and losses incurred by convective accel-
eration along the lesion (increasing with the square of flow, Bernoul-
li’s Law). Due to flow separation and eddy formation, these pressure
losses are not recovered at the stenosis exit.
Fractional flow reserve
When coronary resistance is minimized by pharmacological vaso-
dilatation, there is an approximately linear (more accurately defined
as incremental-linear) relationship between perfusion pressure and
blood flow within the physiological blood pressure range.1,11
Myocardial FFR (FFRmyo) is defined as the maximal blood flow to
the subtended myocardium in the presence of a stenosis compared
with maximal flow in the absence of a stenosis.1,14 Using a pressure-
sensitive coronary wire, FFR is calculated from the coronary pressure
distal to a stenosis (Pd) and the aortic pressure (Pa) obtained simultan-
eously by a haemodynamic pressure transducer, both measured un-
der conditions of maximal hyperaemia: FFRmyo ¼ Pd/Pa (Figure 1).14
By measuring the coronary wedge pressure (Pw) during maximum
hyperaemia, the contribution to myocardial blood flow from
sources other than the epicardial artery (such as collateral and
venous flow) can be assessed and analysed separately.14 This is
the coronary FFR (FFRcor ¼ [Pd2 Pw]/[Pa2 Pw]). Myocardial FFR
is normally used in practice and in most cases incorporation of
Pw makes no difference to the decision for revascularization.
14
Fractional flow reserve threshold
for ischaemia
Based on repeated non-invasive stress testing, the FFR threshold for
discriminating clinically significant lesion-level ischaemia is 0.75,15
and revascularization decisions based on this threshold are
evidence-based.16 In order to increase measurement sensitivity to
reliably exclude the presence of functionally significant stenoses, a
threshold of 0.80 has been adopted and is now evidence-
based.17– 19 However, when a treatment decision is made involving
FFR, it is good practice to take account of other clinical information,
including the medical history, CAD characteristics, and the myocar-
dial territory-at risk.3,4
When should central venous pressure be
measured?
Strictly, the calculation for FFR should account for right atrial pres-
sure (Pv): FFRmyo ¼ [Pd2 Pv]/[Pa 2 Pv].14 However, pragmatically,
venous pressure is not usually measured in daily clinical practice
and Pv was not used for FFR calculation in the landmark clinical
trials.17 – 19 This reflects the fact that Pv has minimal influence on
FFR or revascularization decisions. In general, paradoxical
vasoconstriction of the coronary microcirculation does not occur
even in the presence of a severe stenosis.
Pharmacological hyperaemia
Induction of maximal vasodilatation through reductions in myocar-
dial and collateral circulatory resistances is required for accurate
measurement of FFR.1,14 The standard approach for FFR measure-
ment involves administration of intravenous adenosine at a dose of
140 mg/kg/min.20 Intravenous adenosine reduces systemic and coron-
ary vascular resistance and these changes are correlated.21
Fractional flow reserve reproducibility
The VERification of Instantaneous wave-Free ratio and fractional
flow reserve for the assessment of coronary artery stenosis severity
in everydaY practice (VERIFY) was a prospective study of 206 con-
secutive patients with an indication for an FFR measurement who
were simultaneously enrolled in six European centres (4 January–
10 February 2012).22 Fractional flow reserve was measured using
140 mg/kg/min of intravenous adenosine administered for 2 min
and then again after a 2 min rest period. Fractional flow reserve
data were assessed by a central laboratory. The FFR reproducibility
was high (r2 ¼ 0.98) and the limits of agreement were narrow
(20.04 to 20.04). Other studies have also shown minimal FFR vari-
ation with different doses of intravenous adenosine.23,24
Factors that influence the response to
pharmacological vasodilatation and
fractional flow reserve
Treatment decisions should be based on the minimum FFR
value1,14,15 which typically occurs shortly after the onset of
steady-state hyperaemia.25 Occasionally, the minimum FFR value
may occur slightly before steady-state hyperaemia, implying that
the Pd/Pa ratio may not equal the maximum coronary flow ratio be-
tween stenosed and normal artery.26 In this case, the steady-state
FFR may be slightly higher than the minimum FFR in which case
the steady-state FFR should be considered for decision-making.26
Fractional flow reserve values based on at least a 3-beat average
should minimize beat-to-beat variability.25 Fractional flow reserve
measurements across serial lesions should be done slowly in order
to reveal the minimum FFR at specific locations and repeated
measurement of FFR would seem good practice.
Matsuomo et al.27 studied the influence of caffeine (an adenosine
receptor antagonist) on FFR. They observed that in 28 patients with
detectable blood caffeine concentrations FFR values increased with
incremental doses of adenosine (140, 175, and 210 mg/kg/min)
compared with intra-coronary papaverine (10–20 mg) whereas
the FFR results were unrelated to the dose of adenosine in 14
patients who had avoided caffeine for .24 h.
Route of adenosine administration
For intravenous adenosine, steady-state hyperaemia typically requires
at least 1 min to develop meaning that the cardiologist should allow
sufficient time for steady-state conditions to be established.25,26,28 Lim
et al.23 studied a cohort of patients who had an FFR evaluation with
intravenous and intra-coronary adenosine in 238 lesions. They found
C. Berry et al.Page 2 of 13
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a high degree of classification agreement (92.9%; Cohen’s kappa ¼
0.887) for the intravenous vs. intra-coronary routes of administration.
Seto et al.25 found that peripheral and central venous routes of adeno-
sine administration were associated with similar minimum FFR values.
Intra-coronary adenosine is sometimes preferred in practice as it
is simpler to administer and potentially less expensive. In a recent
dose–response study of intra-coronary adenosine on coronary
flow velocity, Adjedj et al.29 found that 60–100 mg of adenosine
in the right coronary artery and 160–200 mg of adenosine in the
left coronary artery safely induced maximum hyperaemia. The
Can cONTrast Injection Better Approximate FFR compAred to
Pure reSTing Physiology (CONTRAST; NCT02184117) study is a
prospective multicentre study involving 750 patients with a clinical
indication for FFR.30 A pre-specified aim of this study is to assess
the equivalence between FFR measured using intra-coronary and
intravenous adenosine. Given the prospective design and large
sample size, this study could provide conclusive information on the
utility of intra-coronary adenosine for pharmacological hyperaemia.
Non-adenosine methods of
pharmacological vasodilatation
Vasodilators other than adenosine have been assessed for FFR measure-
ment, including intravenous regadenoson (a specific A2A receptor agon-
ist),24 and intra-coronary sodium nitroprusside,31 nicorandil, 32 nitrate,33
and papaverine.34 Fractional flow reserve responses are broadly com-
parable for these different pharmacological vasodilator agents.23
Stenosis morphology and
functional significance
Coronary artery stenosis characteristics
and fractional flow reserve
The FFR and Intravascular Ultrasound Relationship Study (FIRST)
was a prospective, multicentre, international registry of 350 patients
[367 lesions; 55% stable angina, 42% acute coronary syndrome
(ACS)] that assessed the relationships between coronary lesion
characteristics revealed by intravascular ultrasound (IVUS) and
FFR.34 A minimum lumen area (MLA) of ,3.07 mm2 had moderate
accuracy [area-under-the curve (AUC) ¼ 0.65] for identifying an
FFR of ,0.80, and the AUC increased with increasing vessel diam-
eter (a surrogate for subtended myocardial volume). Plaque burden
had a weak positive correlation with FFR (r ¼ 20.22, P, 0.001).
Thin-cap fibroatheroma and calcification were associated with low-
er correlations between MLA and FFR. The multivariable correlates
of FFR were MLA by IVUS, diameter stenosis by QCA, and left an-
terior descending (LAD) coronary artery (vs. right coronary artery).
Iguchi et al.35 found a strong inverse correlation between lesion
length and FFR value. Lo´pez-Palop et al.36 suggested that a length
of .20 mm was the strongest morphological determinant of func-
tional significance. Takashima et al.37 found that lesion complexity
(assessed by QCA) correlated with FFR, with the hypothesis that
with increasing complexity there are greater pressure losses due
to flow separation and friction. In a multivariate analysis, Cho
Figure 1 Systemic and coronary vascular beds that influence FFR.14 Ao, aortic pressure; Pa, arterial pressure proximal to stenosis; Pd, coronary
pressure distal to epicardial stenosis; Pv, venous pressure; Qc, collateral blood flow; Rc, collateral resistance; Rs, epicardial coronary stenosis;
FFR, fractional flow reserve; IMR, index of microvascular resistance; CFR, coronary flow reserve.
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et al.38 assessed the factors associated with mismatch between FFR
and QCA in 643 lesions (n ¼ 462 patients). They observed that le-
sion location (LAD vs. non-LAD) predicted FFR and that QCA para-
meters were more likely to over-estimate stenosis severity (vs. FFR)
in non-LAD lesions and short lesions. Reference vessel diameter
and multi-vessel disease were associated with over- and underesti-
mation of the physiological significance, respectively. Leone et al.39
found an inverse correlation between the amount of subtended
myocardium and the FFR value. Quantitative coronary analysis can-
not accurately predict FFR as it does not account for the volume of
distribution of the coronary artery nor for the function of the micro-
circulation within that coronary territory. In summary, morphological
parameters of stenosis severity influence FFR but are not a reliable sub-
stitute for physiological assessment.
Age and gender influences on fractional
flow reserve
Fractional flow reserve measured in a coronary artery without
atherosclerosis approximates 1.0 irrespective of age or sex, where-
as this may not be the case in flow-derived indices such as coronary
flow reserve (CFR) or hyperaemic stenosis resistance (HSR).
Age-related changes in cardiac structure (e.g. interstitial fibrosis)
and coronary disease (e.g. microvascular dysfunction) may influence
FFR. In a post hoc analysis of the FAME trial participants, Lim et al.40
observed that the mean FFR value obtained in older patients (.65
years) was higher than that in patients ,65 years (0.72+ 0.17 vs.
0.70+0.18; P ¼ 0.043), and that for any given angiographic stenosis
severity the FFR value was more likely to be higher in older subjects.
However, FFR-guided percutaneous coronary intervention (PCI)
was equally beneficial regardless of age,40 reflecting similar potential
for flow-augmentation after PCI.1,11,12 Ageing was also a multivari-
able associate of overestimation of disease severity in the analysis
by Cho et al.38
The IRIS FFR-DEFER registry of 700 patients reported that for the
same degree of angiographic stenosis severity women were more
likely to have higher FFR values.41 Li et al.42 reported a similar finding
in a retrospective study of 1090 patients. The potential explanations
for this discrepancy include an increased prevalence of microvascu-
lar disease in females and a lower body surface area and myocardial
mass resulting in a smaller subtended myocardial territory for a
given stenosis compared with males.
Fractional flow reserve and microvascular
function: complementary use of fractional
flow reserve, coronary flow reserve, and
index of microvascular resistance
The index of microvascular resistance (IMR) is a guidewire-based
quantitative measure of microvascular resistance.43 – 46 As IMR is
measured during hyperaemia, it is less dependent on haemodynamic
variations and has better repeatability than CFR. Index of micro-
vascular resistance is calculated from distal coronary pressure (Pd)
multiplied by the mean transit time (Tmn) of a 3 mL bolus of room tem-
perature saline during hyperaemia induced by intravenous adenosine,
where IMR¼ Pd × Tmn. An IMR, 25 is considered normal, with va-
lues greater than this consistent with microvascular dysfunction.
Complementary use of fractional flow reserve, coronary
flow reserve, and index of microvascular resistance in daily
clinical practice
Combining FFR with CFR and IMR measurements in daily clinical
practice can give clinicians instantaneous and complementary diag-
nostic information on epicardial CAD and microvascular function in
the catheter laboratory (for reviews, 46–48; Figure 2). This ap-
proach may be particularly relevant in a subset of patients presenting
with angina, non-invasive evidence of ischaemia, but no significant
epicardial CAD (FFR. 0.80).49,50 In patients with non-obstructive
atheroma (FFR. 0.8), an impaired CFR and an increased IMR indi-
cates the presence of coronary microvascular disease. In contrast, in
patients without obstructive epicardial CAD (by angiography or
FFR), an impaired CFR and a normal IMR, diffuse atherosclerotic
CAD may cause ‘low-flow’ ischaemia.47 In this situation, increasing
atherosclerotic plaque burden is offset by vessel remodelling which
preserves the vessel lumen diameter. With no focal stenosis, there is a
lack of convective acceleration through the vessel and thus distal pres-
sure loss is limited (FFR. 0.8) even if CFR is significantly impaired.48
The discordance between FFR and CFR (i.e. normal FFR and abnormal
CFR) may be prognostically important.51 The Distal Evaluation of Func-
tional Performance With Intravascular Sensors to Assess the Narrow-
ing Effect – Combined Pressure and Doppler FLOW Velocity
Measurements (DEFINE-FLOW) study will prospectively examine a
management strategy that combines FFR and CFR to inform treatment
decisions in 500 patients with CAD. In this study, patients with a re-
duced FFR but preserved CFR (.2.0) will be treated medically and
PCI will only be performed when FFR and CFR are reduced.52
Other physiological indices
Hyperaemic stenosis resistance is derived from coronary pressure
and Doppler flow measurements.53 The validity of HSR has been
prospectively assessed in a single head-to-head comparison with
myocardial perfusion scintigraphy with Myoview involving doses
of intra-coronary adenosine (20–40 mg) that may have induced
sub-maximal hyperaemia.53 Further validation of HSR has been
undertaken involving post hoc ROC analyses.54 Wider adoption
of Doppler-based indices is limited by reproducibility55 and
pressure-flow diagnostic wires are more expensive than
pressure-only wires.
Recent developments with
fractional flow reserve
Contrast fractional flow reserve
Radiographic contrast media have vasodilator properties and, if
Pd/Pa measured during contrast-induced hyperaemia is already
,0.80, then pharmacological vasodilation might be obviated. Leone
et al.56 assessed 104 coronary stenoses in 80 consecutive patients.
They found that Pd/Pa derived from contrast media was slightly high-
er than FFR derived from intravenous adenosine. The correlation
between these two parameters was strong (r ¼ 0.94, P, 0.001)
and at a cut-off of ≤0.83 contrast Pd/Pa had high diagnostic accuracy
for FFR ≤ 0.80 [AUC ¼ 0.97 (95% CI 0.91–0.99, specificity ¼
96.1%, sensitivity ¼ 85.7%)]. The primary outcome of the CON-
TRAST study30 is the improvement in agreement from resting
C. Berry et al.Page 4 of 13
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Figure 2 Angina associated with inducible ischaemia, non-obstructive epicardial coronary artery disease and microvascular dysfunction re-
vealed by guidewire-based diagnostic tests with FFR, CFR, and IMR. A 70-year-old male presented to the Chest Pain Service with a 2-month history
consistent with Canadian Cardiovascular Society class II angina and hypertension. A treadmill exercise tolerance test disclosed angina and
ST-segment depression in leads II, III, aVF, and V3–V6 at 6 min 52 s at Stage 3 of the Bruce protocol. The patient was invited to participate in
the CE-MARC2 clinical trial (NCT01664858).94 Written informed consent was obtained and he was then randomly assigned to the management
according to the National Institute of Clinical Excellence guideline-95. Based on a pre-test likelihood of coronary artery disease of 60–90%, the
patient was referred directly for invasive management. Coronary angiography revealed multiple plaques (white arrows) in the left (white arrow)
and right (yellow arrow) coronary arteries. The FFR in all three major epicardial arteries was .0.90, ruling out flow-limiting stenoses in these
arteries. The IMR and CFR were 31 and 1.4 in the left circumflex artery and 25 and 2.1 in the right coronary artery, consistent with microvascular
dysfunction. The haemodynamic display from guidewire-based physiological testing in the right coronary artery shows recordings of pressure
(upper panel) measured from the guide catheter in the aorta (red, Ao) and guidewire-based distal coronary pressure (green, Pd), and thermodilu-
tion curves (lower panel) using serial intra-coronary injections of 3 mL of saline at room temperature at rest (blue thermodilution curves, three
curves, mean 0.55 s) and then during adenosine stress [orange thermodilution curves with one highlighted in green (active measurement, 0.22 s,
mean 0.26 s) during a 41 s measurement period (x-axis)]. There is a modest ‘left-shift’ in the thermodilution transit times indicating a reduced
vasodilator response of the coronary microcirculation to intravenous adenosine, consistent with a degree of microvascular dysfunction. The pa-
tient was treated medically with 75 mg of aspirin, 40 mg of simvastatin, and angina medications. Permission obtained, Prof. John Greenwood, Prin-
cipal Investigator for the CE-MARC2 trial.94 RCA, right coronary artery; LCA, left coronary artery; FFR, fractional flow reserve; CFR, coronary
flow reserve; IMR, index of microcirculatory resistance.
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indexes (rest Pd/Pa and iFRTM) to contrast Pd/Pa, using FFR ≤ 0.8 as
the binary reference standard.
Smart minimum fractional flow reserve
During a continuous recording with the pressure sensor at a fixed
position in a coronary artery Pd/Pa may fluctuate. Focusing on the in-
herent variability in coronary pressure recordings, Johnson et al.57
demonstrated that despite fluctuating haemodynamics the minimum
measured FFR value is highly repeatable. They have developed a no-
vel ‘smart minimum’ algorithm to select out the highest quality FFR
data within a recording, which should help cardiologists to identify
the minimum FFR value for decision-making. The algorithm is gener-
ic and not commercially restricted.
Diastolic fractional flow reserve
Coronary blood flow is predominantly in diastole and segmentation
of FFR to diastole (dFFR) might have higher diagnostic accuracy for
the detection of ischaemia.58,59 In a post hoc analysis of the VERIFY
study, we found near equivalent diagnostic accuracy for whole-cycle
and dFFR with an AUC of 98% in an ROC analysis for diastolic FFR
predicting FFR ≤ 0.80 (N.L. Johnson, personal communication). In
reality, full-cycle FFR and dFFR have similar diagnostic value.
Fractional flow reserve estimated
from cardiac imaging based on
computational fluid dynamics
Fractional flow reserve from computed
tomography coronary angiography
Fractional flow reserve can now be estimated non-invasively from
high-quality computed tomography (CT) coronary angiograms.
The DISCOVER-FLOW study examined the relationships between
non-invasive FFR (FFR-CT) vs. FFR measured invasively in 159 arter-
ies in 103 patients and reported that adoption of FFR-CT markedly
improved the diagnostic accuracy of the CT scan.60 The larger
HEARTFLOW-NXT trial incorporated further developments with
the FFR-CT technology and in a stringent protocol involving a
selected patient population diagnostic accuracy for FFR-CT was
further improved.61
Fractional flow reserve from invasive
coronary angiography
Fractional flow reserve can be estimated using 3-D angiography,
TIMI frame count (FFR-QCA),62 and also from rotational angiog-
raphy images alone [virtual FFR (vFFR)63]. These promising develop-
ments should undergo further studies in larger unselected patient
populations.
Resting pressure indices measured
invasively: an alternative to
fractional flow reserve?
Mamas et al.64 originally described the relationships between resting
and hyperaemic pressure measurements in 528 pressure wire
recordings obtained in 483 patients. They found that for an FFR
ischaemic threshold (≤0.75), a whole-cycle Pd/Pa cut-off of ≤0.85
had a positive predictive value of 95% and Pd/Pa of ≥0.93 had a nega-
tive predictive value of 95.7%. One other study reported near 100%
diagnostic accuracy with a Pd/Pa adenosine zone of 0.87–0.99.
65
The instantaneous wave-free ratio (iFRTM)
iFRTM involves estimation of the trans-stenotic pressure gradient at
rest during a time interval starting 25% into diastole and ending 5 ms
before the onset of systole using a trademarked algorithm. iFRTM
was originally described in 2011 by the ADVISE investigators who
proposed that an iFRTM cut-off value of 0.83 was equivalent to an
FFR value of 0.80.66 More recently this cut-off value has been revised
upwards to 0.89–0.9067 and a hybrid strategy is also proposed.68
The VERIFY22 and RESOLVE69 studies called into question the diag-
nostic accuracy of resting pressure indices vs. FFR stimulating further
investigations,30,67– 75 including head-to-head comparisons of iFRTM
vs. FFR-guided management in clinical trials designed to assess
health outcomes.74,75
Fractional flow reserve in stable
coronary disease: results from
single and multicentre cohort
studies
Park et al.76 reported data from the large single-centre ASAN PCI
registry in which 2699 patients had PCI performed before FFR
was in routine use and 2398 after it became the standard of care.
Fractional flow reserve was used in lesions with diameter stenosis
severity between 50 and 80% when there was no prior evidence
of ischaemia. Percutaneous coronary intervention was undertaken
if the FFR is ,0.75 and deferred if FFR is .0.8. ‘Grey zone’ results
were left to the operator’s discretion. The primary endpoint of the
study was a combination of death from any cause, MI, and repeat re-
vascularization at 1 year. In a propensity-matched analysis, com-
pared with the angiography-guided population, the primary
endpoint was lower in the FFR-guided population (8.6 vs. 4.8%,
P, 0.001) with a hazard ratio of 0.55 (95% CI 0.43–0.7, P,
0.001). This result was mainly attributed to less peri-procedural
MI and repeat revascularization, despite a lower use of stents.
Frohlich et al.77 analysed the London PCI registry (2004–2011) in
which FFR was used according to operator discretion. The FFR
group had an unadjusted all-cause mortality benefit (HR 0.72, 95%
CI 0.61–0.84, P, 0.001) though there was no association with
mortality when the data were adjusted for confounders.
A propensity-matched analysis of FFR vs. angiography-alone (919
pairs) showed no difference in mortality (P ¼ 0.32) but with a lower
mean stent number in the FFR group (1.1 vs. 1.7, P, 0.001). The
publication lacked information on medically managed patients.
Li et al.78 reported follow-up results of a similar analysis of 7050
patients from the Mayo Clinic registry (2002–2009). They found
lower MACE with FFR guidance compared with angiographic guid-
ance (50 vs. 57%, P ¼ 0.016). Fractional flow reserve-guided revas-
cularization in patients with bypass grafts is also associated with a
better outcome and lower costs.79
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Deferral of revascularization and adoption
of medical therapy alone
Depta et al.80,81 retrospectively analysed the outcomes of 720 (881
intermediate lesions) patients in whom PCI was deferred following
FFR measurement between 2002 and 2010. Lesions were divided
into three groups according to FFR: grey zone (0.75–0.8; n ¼ 65);
borderline (0.81–0.85; n ¼ 275), and non-borderline (.0.85; n ¼
541). One hundred and fifty-seven (18%) patients required deferred
lesion intervention during 4.5+2.1 years follow-up. Of these, 117
had PCI and 40 had coronary artery bypass graft surgery (CABG).
Overall, one in four stenoses with a borderline FFR (0.81–0.85) re-
quired intervention during the study follow-up period. The rate of
subsequent MI following deferral based on FFR was 11% and the
deferred lesion was the culprit in 38%.
Van de Hoef et al.13 measured FFR and coronary flow velocity re-
serve (CFVR) in one intermediate stenosis in 157 patients in whom
revascularization was deferred. During 10 years of follow-up, a nor-
mal FFR with abnormal CFVR was associated with more MACE re-
gardless of whether an FFR cut-off of 0.75 or 0.80 was used. One
explanation for this discordance is that whilst successful revasculariza-
tion should negate the prognostic impact of a lesion with an ischaemic
FFR, this effect may be attenuated if post-PCI CFR remains abnormal.
The DEFINE-FLOW study will focus on this question.52
Reclassification of treatment decisions
during angiography
The RIPCORD study was designed to assess whether routine FFR
measurement during diagnostic coronary angiography would impact
the management of patients when compared with angiographic as-
sessment.82 Two hundred patients with stable angina were enrolled
in 10 UK centres. The main result was that the management plan
(medical therapy alone, PCI, CABG, or more information required)
changed in 26% of the population. The results of the Registre
Franc¸ais de la FFR (R3F) in 1075 consecutive patients enrolled in 20
centres83 were consistent with those of RIPCORD in that
reclassification of management with FFR was common (43% of the
cases; revascularization reduced overall). In addition, clinical out-
comes at 1 year were not compromised by deciding the treatment
plan based on FFR.
Prognostic importance of fractional
flow reserve
The meta-analysis of study-level (n ¼ 9173) and individual patient-
level (n ¼ 6961) data by Johnson et al.84 has provided new in-
formation on the prognostic importance of individual FFR values.
Put simply, clinical events increased as FFR decreased and FFR mea-
sured post-PCI had an inverse relationship with prognosis (hazard
ratio: 0.86, 95% CI 0.80–0.93; P, 0.001). Fractional flow reserve-
guided management reduced MACE (Figure 3) and angina. This ana-
lysis affirms the prognostic importance of the FFR value (as opposed
to an FFR binary cut-off value) and indicates that patients who have
a low-normal FFR value, i.e. 0.81–0.85, have a higher likelihood of
future adverse cardiac events compared with patients with a near-
normal FFR value, i.e. 0.96–1.0. Although evidence from rando-
mized trials is lacking, a pragmatic clinical approach would be to
prescribe more intensive preventative therapy in patients with
lower FFR values, including after PCI.80,81
Fractional flow reserve in stable
coronary disease: results from
multicentre clinical studies
The FAME-2 trial enrolled 1220 patients with stable CAD.18 Of
these, 888 patients with at least one functionally significant stenosis
(FFR ≤ 0.80) in whom PCI was intended were randomized to either
PCI with optimal medical therapy (OMT) or OMT alone.
Drug-eluting stents were used almost exclusively. The study was
stopped prematurely by the Data Safety Monitoring Board due to
a statistically significant reduction in hospital re-admission for urgent
revascularization in the PCI group. Clinical outcomes in the PCI
Figure 3 Prognostic importance of fractional flow reserve values below and above the ischaemic zone (0.75–0.80).84
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patients were similar to those in the registry patients who had no
ischaemia in the first place (FFR. 0.80) (Figure 4). The FAME-2 de-
sign involved unblinded treatment assignment thus participants in
the OMT group and their clinicians were aware that PCI had been
cancelled by protocol. The definition of urgent coronary revascular-
ization for the primary outcome required both an urgent unplanned
hospital admission with persistent or increasing symptoms (with or
without ECG changes or elevated biomarker levels) and that the re-
vascularization be performed within 24 h of admission. Cardiolo-
gists blinded to the treatment group assignment adjudicated this
outcome. The 2-year primary outcome results reaffirmed the initial
results.19
In patients with moderate–severe ischaemia revealed by non-
invasive testing, the impact of invasive management with OMT vs.
medical therapy alone on cardiovascular death and non-fatal MI is
currently being assessed in the International Study of Comparative
Health Effectiveness With Medical and Invasive Approaches
(ISCHEMIA) trial (sample size, n ¼ 8000).85
In summary, in stable CAD, the evidence-base supports revascu-
larization of lesions with an FFR of ≤0.80 whereas CAD associated
with an FFR of .0.80 can be managed medically.
Fractional flow reserve in acute
coronary syndromes
The diagnostic validity of FFR is less certain in ACS patients partly
because of concerns that the response to pharmacological vasodila-
tation may be reduced due to culprit artery microvascular obstruc-
tion leading to false-negative FFR values. Accordingly, FFR is not
valid in the culprit artery of STEMI patients.86 However, FFR may
be useful in NSTEMI patients since culprit (and non-culprit) ante-
grade flow is usually preserved.
The FAMOUS-NSTEMI trial (NCT01764334) was the first multi-
centre, randomized trial of routine FFR-guided management vs. stand-
ard invasive management in ACS patients.87,88 Three hundred and fifty
medically stabilized patients with an NSTEMI were randomized and an
Figure 4 FAME-2 long-term follow-up. Cumulative incidence of the primary endpoint (death, myocardial infarction, or urgent revascularization)
and its components.19
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initial treatment decision was made following the coronary angiogram
and before FFR measurement. Where feasible, FFR was performed in
each artery containing at least one lesion of ≥30% diameter stenosis
by visual estimation but in the patients randomized to angiographic
guidance, the FFR results remained blinded. The primary outcome
was the between-group difference in the proportion of patients allo-
cated to medical management. A higher proportion of patients were
treated with medical therapy only in the FFR group compared with the
angiography-guided group (22.7 vs. 13.2%; P ¼ 0.022) (Figure 5). In
other words, the use of FFR reduced revascularization. As in
FAME,17 there was marked discordance between the visual assess-
ment of stenosis severity and functional significance defined by FFR.
Of 350 patients (n ¼ 706 lesions), an FFR result was obtained in
100% of the participants and only two coronary dissections occurred
due to the pressure wire, indicating routine FFR measurement was
feasible and safe. There were no adverse events relating to intraven-
ous adenosine. There was no difference in MACE between the
groups and other health and economic outcomes were similar.
FAMOUS-NSTEMI87,88 differed by design from FAME17 in that it
only enrolled NSTEMI patients, all treatment options (medical ther-
apy, PCI, and CABG) were possible, FFR was recorded but not dis-
closed in the angiography-guided group, and the stenosis cut-off
value for enrolment in FAMOUS was ≥30% whereas in FAME it
was ≥50%. The purpose of adopting this wider range of stenosis se-
verities in FAMOUS-NSTEMI was to provide data on the relation-
ship between ‘mild’ lesions and FFR. A 3.0 Tesla stress perfusion
magnetic resonance imaging sub-study in FAMOUS has recently
provided evidence that FFR retains diagnostic validity in medically
stabilized NSTEMI patients.89 A large trial of FFR-guided manage-
ment in NSTEMI patients that is designed and powered to assess
health and economic outcomes now seems warranted.
Recent developments with
fractional flow reserve in the
clinical guidelines for stable
coronary artery disease
The current guidelines for stable CAD3 and myocardial revascular-
ization4 reaffirm the diagnostic value of FFR and that FFR-guided
PCI with medical therapy is evidence-based to decrease the
need for urgent revascularization compared with OMT alone.
The guidelines state that deferral of PCI or CABG based on an
FFR .0.80 appears safe. The adoption of FFR has a Class I (Level
of Evidence A) recommendation when prior evidence of ischaemia
is not available. Fractional flow reserve-guided PCI has a Class IIa
(Level of Evidence B) recommendation in patients with multi-
vessel coronary disease. The guidelines for stable CAD3 recom-
mend consideration of direct referral of patients with severe an-
gina or a high pre-test probability of CAD (.85% likelihood) for
early invasive coronary angiography, and since information on in-
ducible ischaemia may then be lacking treatment decisions in the
catheter laboratory should be informed by measurement of FFR
where appropriate (Class I recommendation, Level of Evidence
C). Coronary angiography with FFR should also be considered
for risk stratification in patients with an inconclusive diagnosis on
non-invasive testing or when conflicting results arise from different
test modalities (Class IIa, Level of Evidence C). Revascularization of
angiographically intermediate lesions without ischaemia or with-
out an FFR , 0.80 is not recommended (Class III recommenda-
tion, Level of Evidence B). The guidelines also mention that
non-invasive FFR requires further validation before its clinical
use may be justified.3,4
Figure 5 Impact of fractional flow reserve disclosure on treatment decisions based on standard angiography-alone in the FAMOUS-NSTEMI
clinical trial.87
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These guidelines are evidence-based recommendations, but they
are not presented as binding requirements. The FFR threshold of
0.80 represents the upper limit of a transition zone for flow-limiting
coronary disease, and as mentioned above, patient-specific factors in-
fluence the FFR value. Good clinical practice should take into account
all relevant information when making a revascularization decision.
Recent developments on fractional
flow reserve in the guidelines for
acute coronary syndromes
In the guidelines for the management of patients presenting without
persistent ST-segment elevation,90 FFR is described as useful in
patients with intermediate lesions .5 days after the index event.
Fractional flow reserve may be helpful to decide upon the treatment
strategy, and in patients with multi-vessel disease, FFR may help to
assess non-culprit lesions as part of a sequential management
approach involving the ‘Heart Team’. The STEMI guidelines91 state
that FFR may be used to assess non-infarct arteries as part of a
staged revascularization approach planned for days or weeks after
the initial primary PCI.
Current trials in stable coronary artery
disease and acute coronary syndrome
and future prospects
The current trials of FFR-guided strategies are highlighted in Supple-
mentary material online, File S1. The potential clinical utility of an
FFR-guided management in STEMI patients with multi-vessel CAD
is being studied in DANAMI-3-PRIMULTI,92 COMPARE-ACUTE,93
and COMPLETE.94
Conclusions and future horizons
As the FFR evidence-base evolves, so will the rationale for functional
testing of CAD severity. An assessment of published studies using
quality criteria (Supplementary material online, File S1) indicates
that retrospective analyses in selected patient cohorts involving
comparisons of diagnostic indices without masking (blinding) and/
or independent analysis are common. The quality of diagnostic
studies in the future must improve.
Emerging developments with diagnostic coronary guidewires
include a diagnostic rapid exchange FFR microcatheter (ACIST
NAVVUSTM), and solid-state pressure wires with optical technology
with the potential to overcome pressure drift (e.g. OPSENSTM;
POLARISTM, Boston Scientific), and potentially measurement of
absolute coronary flow may become possible.
Supplementary material
Supplementary material is available at European Heart Journal online.
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